TQ’s impact as a new radical cure drug agent against P. vivax malaria has been constrained in part by the risk of hemolytic toxicity in G6PD-deficient human populations that are largely coincident with the malaria belt geography (23, 25, 71, 72). The gene discussed is G6PD; the disease is malaria.